A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction among Individuals with History of Colorectal Adenomas and Elevated Body Mass Index
- J. ZellC. McLaren F. Meyskens
- 9 December 2019
Medicine
Among obese patients with CRA, 12 weeks of oral meetformin does not reduce rectal mucosa pS6 or Ki-67 levels, and further research is needed to determine what effects metformin has on the target tissue of origin as metform in continues to be pursued as a colorectal cancer chemopreventive agent.
Prevention of colonic neoplasia with polyethylene glycol: A short term randomized placebo-controlled double-blinded trial
- R. WaliL. Bianchi H. Roy
- 4 April 2018
Medicine
It is concluded that PEG was generally well tolerated with the trial failing to meet primary efficacy endpoints, however, rectal ACFs demonstrated a trend for suppression with PEG, underscoring issues with lack of translatability of biomarkers from preclinical to clinical trials.
Sa1859 Randomized Double Blind Placebo Controlled Phase II Trial of Barrett's Esophagus Chemoprevention With Metformin
- A. ChakN. Buttar P. Limburg
- 1 May 2014
Medicine
548 Correlation of Spectral Signatures With Rectal Prostaglandin E2 Levels As Biomarkers for Aspirin Chemoprevention of Colon Carcinogenesis: Results From a Placebo-Controlled Double Blinded Phase 2B…
- H. RoyV. Turzhitsky V. Backman
- 1 May 2014
Medicine
376 Aspirin May Reduce the Risk of Gastric, but Not Esophageal Adenocarcinoma: A Prospective Cohort Analysis
- Jigarkumar A. PatelP. Pinsky L. M. Rodriguez
- 1 April 2015
Medicine
883 Characteristics Associated With Rectal Aberrant Crypt Foci in a High-Risk Subject Population
- P. LimburgM. Mahoney T. Smyrk
- 1 May 2012
Medicine
Mo1161 Phase 2B Randomized Placebo-Controlled Spectral Markers As Biomarkers for Colonic Chemoprevention With Aspirin: Correlation With Rectal Apoptosis but Not Proliferation
- H. RoyA. Radosevich V. Backman
- 1 May 2013
Medicine
CLINICAL, LABORATORYAND TREATMENT PROFILE OF CHILDREN DIAGNOSEDWITH ENTHESITIS-RELATED ARTHRITIS, CHILDHOOD-ONSETAXIAL SPONDYLARTHRITIS OR BOTH IN NORTHWESTERN COLOMBIA: A CROSS-SECTIONAL STUDY
In this series, approximately 11% of switching patients failed after a 6-month of follow-up; the median persistence time in the original molecule and the percentage of failures observed in AS could be two conditions to consider before switching.
Abstract 3247: SAMe versus placebo for the reduction of serum AFP in patients with hepatitis C cirrhosis and moderately elevated AFP: A randomized, placebo-controlled, double-blind phase II trial
- T. MorganF. Meyskens L. M. Rodriguez
- 1 October 2014
Medicine
SAMe administration for 24 weeks in patients with HCV-C and elevated AFP did not decrease AFP significantly nor alter liver function, but SAMe significantly increased serum SAMe and SAH levels, but did not alter serum glutathione level or serum markers of oxidative stress.
...
...